“Omalizumab Dose Step-Up and Treatment Response in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results from the OPTIMA Study”, J of Skin, vol. 2, no. S1, p. S52, Feb. 2018, doi: 10.25251/skin.2.supp.52.